Psoriatic arthritis
O FitzGerald, A Ogdie, V Chandran… - Nature reviews Disease …, 2021 - nature.com
Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical
features, which complicates psoriasis in 30% of patients. There are no diagnostic criteria or …
features, which complicates psoriasis in 30% of patients. There are no diagnostic criteria or …
Systematic review of mental health comorbidities in psoriatic arthritis
Objective In this systematic review and meta-analysis of psoriatic arthritis (PsA) studies, we
pooled data from existing literature to (1) estimate the prevalence of mental health disorders …
pooled data from existing literature to (1) estimate the prevalence of mental health disorders …
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double …
JF Merola, R Landewé, IB McInnes, PJ Mease… - The Lancet, 2023 - thelancet.com
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with …
(IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with …
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a …
PJ Mease, JS Smolen, F Behrens, P Nash… - Annals of the …, 2020 - ard.bmj.com
Objectives To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
IB McInnes, F Behrens, PJ Mease, A Kavanaugh… - The Lancet, 2020 - thelancet.com
Background Head-to-head trials in psoriatic arthritis are helpful in guiding clinical decision
making. The EXCEED study evaluated the efficacy and safety of secukinumab versus …
making. The EXCEED study evaluated the efficacy and safety of secukinumab versus …
Psoriatic arthritis: exploring the occurrence of sleep disturbances, fatigue, and depression and their correlates
G Haugeberg, M Hoff, A Kavanaugh… - Arthritis Research & …, 2020 - Springer
Introduction Sleep disturbances, fatigue, and anxiety/depression in psoriatic arthritis (PsA)
may be influenced by skin and musculoskeletal manifestations. All of these in turn affect the …
may be influenced by skin and musculoskeletal manifestations. All of these in turn affect the …
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year …
Objective We evaluated real-world treatment persistence and effectiveness at 1 year
following initiation of IL-12/23 inhibitor ustekinumab or a tumour necrosis factor inhibitor …
following initiation of IL-12/23 inhibitor ustekinumab or a tumour necrosis factor inhibitor …
Improvement in patient-reported outcomes in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: results from SELECT-PsA 1
V Strand, PJ Mease, ER Soriano, M Kishimoto… - Rheumatology and …, 2021 - Springer
Introduction The aim of this work is to assess the effect of upadacitinib versus adalimumab
and placebo on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) patients with …
and placebo on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) patients with …
Efficacy of Secukinumab and Adalimumab in patients with Psoriatic arthritis and concomitant Moderate‐To‐Severe plaque psoriasis: results from EXCEED, a …
AB Gottlieb, JF Merola, K Reich… - British journal of …, 2021 - academic.oup.com
Background Secukinumab [an interleukin (IL)‐17A inhibitor] has demonstrated significantly
higher efficacy vs. etanercept (a tumour necrosis factor inhibitor) and ustekinumab (an IL …
higher efficacy vs. etanercept (a tumour necrosis factor inhibitor) and ustekinumab (an IL …
Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase 3 …
K Houghton, D Patil, B Gomez, SR Feldman - Dermatology and Therapy, 2021 - Springer
Abstract Introduction Patients with psoriasis (PsO) experience impaired health-related
quality of life due to physical and psychosocial burdens. The objective of this study was to …
quality of life due to physical and psychosocial burdens. The objective of this study was to …